Permethrin Shortage: What Providers and Prescribers Need to Know in 2026

Permethrin 5% cream remains the first-line topical treatment for Sarcoptes scabiei infestation per CDC, AAP, and AAFP guidelines, and permethrin 1% lotion is the preferred first-line pediculicide for pediculosis capitis. As of 2026, there is no FDA-declared national shortage in the US — but clinicians in many regions are fielding calls from patients who cannot find permethrin at local pharmacies. This article summarizes the current landscape and provides clinical guidance for managing patients when permethrin is unavailable or fails.

Current Supply Situation (US, 2026)

The FDA's drug shortage database does not currently list permethrin 5% cream or permethrin 1% lotion as nationally shortage drugs. However, clinicians should be aware that:

Localized pharmacy-level stockouts are common, particularly in areas experiencing community outbreaks of scabies or pediculosis in institutional settings (nursing homes, correctional facilities, schools).

The UK experienced a declared shortage in September 2023, affecting both permethrin 5% cream and malathion simultaneously — a scenario that could theoretically occur in the US during a major outbreak.

Generic permethrin is manufactured by a limited number of suppliers; disruptions to any can cause regional shortages without triggering an FDA national shortage designation.

Permethrin Resistance: Clinical Implications

Treatment failure with permethrin is increasingly reported in the literature. Key findings:

A 2025 systematic review (Clinical Dermatology and Surgery) found rising permethrin treatment failures in scabies, with resistance patterns varying by geographic region.

A recent European study detected permethrin-resistant scabies in nearly 3 out of 4 cases, with benzyl benzoate showing higher cure rates in this population.

For head lice, permethrin resistance via "knockdown resistance" (kdr) mutations has been documented across much of North America and Europe.

Clinical pearl: When a patient reports treatment failure, first confirm correct application technique before assuming resistance. Permethrin 5% cream must be applied from head to toe, left on for 8-14 hours, and all household contacts must be treated simultaneously.

Evidence-Based Alternatives When Permethrin Is Unavailable

For Scabies

Oral ivermectin 200 mcg/kg x2 (14 days apart): Comparable efficacy to permethrin after 2 weeks per RCT data. Preferred for institutional outbreaks (easier mass administration), crusted scabies (combine with topical), or failure of topical therapy. Not approved for children <15 kg or pregnant women.

Crotamiton 10% cream/lotion (Eurax): FDA-approved; applied on 2 consecutive nights, washed off 48 hours after second application. Lower cure rate than permethrin but useful for patients unable to take ivermectin. Antipruritic effect is an added benefit.

Precipitated sulfur 6% ointment: Not FDA-labeled for scabies but widely used; considered safe in pregnancy and for infants <2 months. Applied nightly for 3 nights. Available from compounding pharmacies.

For Pediculosis Capitis

Spinosad 0.9% (Natroba): Effective against permethrin-resistant lice; single 10-minute application usually curative. Approved for patients ≥4 years. First-choice when kdr resistance is suspected.

Malathion 0.5% lotion (Ovide): Recommended by CDC as an alternative when permethrin resistance is suspected; applied to dry hair for 8-12 hours. Highly flammable — warn patients explicitly. Approved for patients ≥6 years.

Benzyl alcohol 5% lotion (Ulesfia): Non-neurotoxic mechanism; no cross-resistance with pyrethroids. Approved ≥6 months; 2 applications 7 days apart.

Oral ivermectin (off-label for lice): Not FDA-approved for pediculosis but used off-label; 400 mcg/kg x2 doses (7-10 days apart). May be appropriate for refractory cases.

Special Populations: Pregnancy and Infants

Permethrin 5% cream remains the preferred treatment for scabies and pubic lice during pregnancy (CDC recommendation), as it has an excellent safety profile (former FDA Pregnancy Category B) with less than 2% systemic absorption. For pediculosis capitis in pregnancy, permethrin 1% lotion remains first-line.

Permethrin 5% cream is also approved for use in infants 2 months and older. For infants under 2 months, precipitated sulfur 6% ointment is the preferred off-label option. Oral ivermectin is not recommended in children under 15 kg.

Helping Patients Find Permethrin When Pharmacies Are Out

When patients call your office because they cannot find permethrin, direct them to medfinder. medfinder contacts pharmacies in the patient's area to find which ones can fill their specific prescription, then texts results directly to the patient — reducing callbacks to your office and getting patients treated faster.

Summary of Recommendations

Permethrin remains first-line for scabies and head lice; no national US shortage as of 2026.

Have a documented alternative regimen ready (oral ivermectin or crotamiton for scabies; spinosad or malathion for lice).

Before diagnosing resistance, confirm correct application technique with the patient.

For institutional outbreaks, oral ivermectin is logistically easier for mass treatment; consult an infectious disease specialist for complex cases.

Direct patients with pharmacy access difficulties to medfinder.com or compounding pharmacy options.